Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStomach issues are the most commonly reported side effects of Mounjaro (tirzepatide), affecting the majority of people at some point during treatment — particularly in the first few weeks or after a dose increase. Nausea, bloating, loose stools and discomfort are well-documented and, for most people, settle on their own. That said, a small number of gastrointestinal symptoms can signal something more serious, so knowing how to tell them apart matters. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro activates two gut-hormone receptors (GIP and GLP-1) which together reduce appetite and slow the rate at which food moves from the stomach into the small intestine. That slowing of gastric emptying is intentional: it prolongs the feeling of fullness after a meal. The trade-off is that food sits in the stomach longer than usual, which can produce nausea, bloating, burping and a sensation of uncomfortable fullness even after small portions.
The NHS tirzepatide medicines page lists the most common side effects as nausea, diarrhoea, vomiting, constipation, stomach pain, indigestion and reflux, all directly linked to this slowed transit. For most people these aren't dangerous; they're the body adjusting to a drug that works partly by altering the pace of digestion.
The dose-escalation structure of tirzepatide (starting at 2.5 mg and moving up through six possible strengths) exists largely to give the digestive system time to adapt. Each step up can temporarily revive symptoms that had settled. Eating smaller meals, chewing slowly, avoiding fatty or highly processed foods, and staying hydrated are all practical adjustments that can reduce the intensity. None of that replaces the guidance from your own Mounjaro prescriber, who can advise on whether a slower titration makes sense for you.
A question our prescribers hear most weeks is: "How do I know if this is just the medicine settling or something I should ring 111 about?" It's a fair one, and the honest answer is that the character, location and duration of the discomfort are what matter.
Normal side effects tend to be diffuse and variable, a general queasiness after eating, loose stools for a day or two, bloating that comes and goes, or a feeling of fullness that arrives after the first few bites. These typically peak in the first two to four weeks and improve as the body adjusts. Many people find they're at their worst for 24 to 48 hours after each injection, then gradually subside.
For a broader picture of how these symptoms fit within tirzepatide's overall side-effect profile, the Mounjaro side effects overview covers the full range, gastrointestinal and otherwise. If you're experiencing noticeable skin changes alongside GI symptoms, changes to skin on Mounjaro are discussed separately.
Practical steps that tend to help: eat slowly, keep portions modest, prioritise protein and vegetables over high-fat foods, and drink water consistently rather than in large volumes at once. Ginger-based drinks or plain crackers before eating can ease nausea for some people. These are supportive habits, not substitutes for clinical advice.
Most stomach issues on Mounjaro are an inconvenience rather than a danger. But two presentations deserve prompt medical assessment, not a wait-and-see approach.
The first is severe, persistent abdominal pain that radiates towards the back, with or without vomiting. This pattern can indicate acute pancreatitis, which the MHRA flagged as a known but infrequent serious risk of GLP-1 medicines in its January 2026 Drug Safety Update. It is not common, but it is serious enough that anyone experiencing that specific symptom combination should seek urgent medical help rather than waiting to see if it passes.
The second is sustained vomiting or diarrhoea that makes it impossible to keep fluids down. Dehydration can develop quickly in that situation and carries its own risks, including kidney stress. If you're unable to stay hydrated after several hours, that warrants contacting NHS 111 or your GP the same day.
Less urgently but still worth flagging: if GI symptoms remain severe after four to six weeks at your starting dose without any improvement, that's a conversation to have with your prescriber about whether to pause titration or review the approach altogether. You can also read more about the specific patterns of Mounjaro-related stomach pain and what they typically indicate. Any suspected side effects can be reported directly via the MHRA's Yellow Card scheme.
For most people, yes. Because tirzepatide clears from the body gradually over about a week after the last injection, GI symptoms typically resolve within one to two weeks of stopping. Gastric emptying returns to its usual rate and appetite regulation shifts back toward baseline.
There's a nuance worth knowing, however. Some people notice a temporary change in appetite or digestion in the days immediately following their last dose. If you're considering stopping or have already stopped, what happens to stomach issues after stopping Mounjaro covers that transition in detail.
It's also worth separating the reason for stopping from the experience of stopping. Stopping because side effects were unbearable is different from stopping after reaching your treatment goals, and the clinical picture around both is different. Either way, don't stop without discussing it with your prescriber first, particularly if you're mid-titration.
If you're weighing up Mounjaro against other approaches or thinking about private treatment for the first time, patients based in the West Midlands can find local prescribing options through our Mounjaro Coventry page, while our consultation page is the starting point for everyone. A prescriber will assess your full clinical picture (including any GI history) before recommending anything.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.